Literature DB >> 2071785

Reexamination of the blood lymphocyte transformation test in the diagnosis of chronic beryllium disease.

M M Mroz1, K Kreiss, D C Lezotte, P A Campbell, L S Newman.   

Abstract

The T cell response to beryllium, measured in bronchoalveolar lavage by the lymphocyte transformation test (LTT), is a critical diagnostic test for discriminating between chronic beryllium disease (CBD) and other granulomatous diseases. We examined the sensitivity, reproducibility, and methods of a less invasive, peripheral blood LTT in 17 patients with CBD and in 18 beryllium-exposed control subjects. Ninety-four percent of CBD cases (16/17) had abnormal blood LTT results, and all 18 beryllium-exposed control subjects had normal blood LTT results. Split samples for 10 beryllium disease cases and eight control subjects demonstrated that the blood LTT was reproducible between two separate laboratories. The LTT was equally sensitive with 10% and 20% serum in the culture medium. We conclude that an abnormal blood LTT can be used to diagnose CBD in patients with compatible lung pathology.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2071785     DOI: 10.1016/0091-6749(91)90300-d

Source DB:  PubMed          Journal:  J Allergy Clin Immunol        ISSN: 0091-6749            Impact factor:   10.793


  39 in total

1.  CD28 costimulation independence of target organ versus circulating memory antigen-specific CD4+ T cells.

Authors:  Andrew P Fontenot; Laia Gharavi; Sean R Bennett; Scott J Canavera; Lee S Newman; Brian L Kotzin
Journal:  J Clin Invest       Date:  2003-09       Impact factor: 14.808

Review 2.  Chronic beryllium disease: an updated model interaction between innate and acquired immunity.

Authors:  Richard T Sawyer; Lisa A Maier
Journal:  Biometals       Date:  2010-10-28       Impact factor: 2.949

Review 3.  The role of lymphocyte proliferation tests in assessing occupational sensitization and disease.

Authors:  Stella E Hines; Karin Pacheco; Lisa A Maier
Journal:  Curr Opin Allergy Clin Immunol       Date:  2012-04

4.  Risks of beryllium disease related to work processes at a metal, alloy, and oxide production plant.

Authors:  K Kreiss; M M Mroz; B Zhen; H Wiedemann; B Barna
Journal:  Occup Environ Med       Date:  1997-08       Impact factor: 4.402

5.  Frequency of beryllium-specific, central memory CD4+ T cells in blood determines proliferative response.

Authors:  Andrew P Fontenot; Brent E Palmer; Andrew K Sullivan; Fenneke G Joslin; Cara C Wilson; Lisa A Maier; Lee S Newman; Brian L Kotzin
Journal:  J Clin Invest       Date:  2005-09-08       Impact factor: 14.808

6.  Beryllium's public relations problem: protecting workers when there is no safe exposure level.

Authors:  David Michaels; Celeste Monforton
Journal:  Public Health Rep       Date:  2008 Jan-Feb       Impact factor: 2.792

7.  Up-regulation of programmed death-1 expression on beryllium-specific CD4+ T cells in chronic beryllium disease.

Authors:  Brent E Palmer; Douglas G Mack; Allison K Martin; May Gillespie; Margaret M Mroz; Lisa A Maier; Andrew P Fontenot
Journal:  J Immunol       Date:  2008-02-15       Impact factor: 5.422

8.  5-Aminosalicylic Acid Modulates the Immune Response in Chronic Beryllium Disease Subjects.

Authors:  Brian J Day; Jie Huang; Briana Q Barkes; May Gillespie; Li Li; Lisa A Maier
Journal:  Lung       Date:  2017-10-27       Impact factor: 2.584

9.  A novel alternative to environmental monitoring to detect workers at risk for beryllium exposure-related health effects.

Authors:  Elizabeth Fireman; Yehuda Lerman; Moshe Stark; Asher Pardo; Yehuda Schwarz; Michael V Van Dyke; Jill Elliot; Briana Barkes; Lee Newman; Lisa Maier
Journal:  J Occup Environ Hyg       Date:  2014       Impact factor: 2.155

10.  Sulfasalazine and mesalamine modulate beryllium-specific lymphocyte proliferation and inflammatory cytokine production.

Authors:  Dave R Dobis; Richard T Sawyer; May M Gillespie; Lee S Newman; Lisa A Maier; Brian J Day
Journal:  Am J Respir Cell Mol Biol       Date:  2009-11-09       Impact factor: 6.914

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.